Belly radiation plus immunotherapy may turn inoperable esophageal cancer into a surgical candidate
NCT ID NCT07339488
First seen Jan 15, 2026 · Last updated May 23, 2026 · Updated 17 times
Summary
This study tests whether a low dose of radiation to the intestine, combined with immunotherapy (tislelizumab) and chemotherapy, can shrink borderline or unresectable esophageal cancer enough to allow surgery. About 43 adults with a specific type of esophageal cancer will receive the treatment over three cycles. The main goal is to see how many patients have no cancer left after the combination therapy.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ESOPHAGEAL SQUAMOUS CELL CARCINOMA (ESCC) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Cancer Hospital, Shantou University Medical College
Shantou, Guangdong, 515031, China
Conditions
Explore the condition pages connected to this study.